14. Immunization and Infectious DiseasesGoal: Prevent disease, disability, and death from infectious diseases,
including vaccine-preventable diseases.
Diseases Preventable Through Universal Vaccination
NO CHANGE IN OBJECTIVE
(Data updated and footnoted)
|
|
14-1.
|
Reduce or eliminate indigenous cases of vaccine-preventable diseases.
|
|
Target and baseline:
|
Objective
|
Reduction in Vaccine-Preventable Diseases
|
1998
Baseline (unless noted)
|
2010
Target
|
|
|
|
Number of Cases
|
|
14-1a.
|
Congenital rubella syndrome (children under age 1 year)
|
7
|
0
|
|
14-1b.
|
Diphtheria (persons under age 35 years)
|
1
|
0
|
|
14-1c.
|
Haemophilus influenzae type b* (children under age 5 years)
|
163
|
0
|
|
14-1d.
|
Hepatitis B (persons aged 2 to 18 years)
|
708†1
|
72
|
|
14-1e.
|
Measles (persons of all ages)
|
74
|
0
|
|
14-1f.
|
Mumps (persons of all ages)
|
666
|
0
|
|
14-1g.
|
Pertussis (children under age 7 years)
|
3,417
|
2,000
|
|
14-1h.
|
Polio (wild-type virus) (persons of all ages)
|
0
|
0
|
|
14-1i.
|
Rubella (persons of all ages)
|
364
|
0
|
|
14-1j.
|
Tetanus (persons under age 35 years)
|
14
|
0
|
|
14-1k.
|
Varicella (chicken pox) (persons aged 17 years and under)
|
2,228,000 (1999)‡3
|
223,0004
|
* Includes cases with type b and unknown serotype.
† Estimated hepatitis B cases for 1997.
‡ Data based on average from 1999 for persons of all ages.
|
|
Target setting method: Total elimination for congenital rubella syndrome, diphtheria, Haemophilus influenzae type b, measles, mumps, polio, rubella, and tetanus; 41 percent improvement for pertussis; 99 percent improvement for hepatitis B and varicella.
|
|
Data
source
s: National Notifiable Disease Surveillance System (NNDSS), CDC, EPO; National Congenital Rubella Syndrome Registry (NCRSR), CDC, NIP–congenital rubella syndrome; Active Bacterial Core Surveillance (ABCs), Emerging Infections Programs, CDC, NCID–Haemophilus influenzae type b; National Health Interview Survey (NHIS), CDC, NCHS–varicella.
|
1 (Baseline revised from 945 after November 2000 publication)
2 (Target revised from 9 because of baseline revision after November 2000 publication)
3 (Baseline and baseline year revised from 4 million and 1990–94 after November 2000 publication)
4 (Target revised from 400,000 because of baseline revision after November 2000 publication)
|
|
|
|
NO CHANGE IN OBJECTIVE
|
|
14-2.
|
Reduce chronic hepatitis B virus infections in infants and young children (perinatal infections).
|
|
|
Target: 400 infections.
|
|
Baseline: 1,682 chronic hepatitis B virus infections in children under age 2 years were reported in 1995.
|
|
Target setting method: 76 percent improvement.
|
|
Data
source
s: Perinatal Hepatitis B Prevention Program, CDC, NCID; National Vital Statistics System (NVSS), CDC, NCHS; State Perinatal Hepatitis B Prevention Programs; State Vital Statistics Systems.
|
|
|
|
|
|
NO CHANGE IN OBJECTIVE
(Data updated and footnoted)
|
|
14-3.
|
Reduce hepatitis B.
|
|
Target and baseline:
|
Objective
|
Reduction in Hepatitis B
|
1997
Baseline
|
2010
Target
|
|
|
Adults
|
Rate per 100,000 Population
|
|
14-3a.
|
19 to 24 years
|
18.51
|
1.82
|
|
14-3b.
|
25 to 39 years
|
20.53
|
5.24
|
|
14-3c.
|
40 years and older
|
14.75
|
3.76
|
|
|
High-risk groups
|
Number of Cases
|
|
14-3d.
|
Injection drug users
|
7,1357
|
1,7848
|
|
14-3e.
|
Heterosexually active persons
|
15,0219
|
1,22310
|
|
14-3f.
|
Men who have sex with men
|
5,20911
|
1,30212
|
|
14-3g.
|
Occupationally exposed workers
|
23913
|
6014
|
|
|
Target setting method: For 14-3a, 14-3b, and 14-3c, better than the best; for 14-3d, 14-3f, and 14-3g, 75 percent improvement; for 14-3e, 92 percent improvement.
|
|
Data
source
s: National Notifiable Disease Surveillance System (NNDSS), CDC, EPO; Sentinel Counties Study of Viral Hepatitis, CDC, NCID.
|
1 (Baseline revised from 24.0 after November 2000 publication)
2 (Target revised from 2.4 because of baseline revision after November 2000 publication)
3 (Baseline revised from 20.2 after November 2000 publication)
4 (Target revised from 5.1 because of baseline revision after November 2000 publication)
5 (Baseline revised from 15.0 after November 2000 publication)
6 (Target revised from 3.8 because of baseline revision after November 2000 publication)
7 (Baseline revised from 7,232 after November 2000 publication)
8 (Target revised from 1,808 because of baseline revision after November 2000 publication)
9 (Baseline revised from 15,225 after November 2000 publication)
10 (Target revised from 1,240 because of baseline revision after November 2000 publication)
11 (Baseline revised from 7,232 after November 2000 publication)
12 (Target revised from 1,808 because of baseline revision after November 2000 publication)
13 (Baseline revised from 249 after November 2000 publication)
14 (Target revised from 62 because of baseline revision after November 2000 publication)
|
|
|
|
NO CHANGE IN OBJECTIVE
|
|
14-4.
|
Reduce bacterial meningitis in young children.
|
|
|
Target: 8.6 new cases per 100,000 children aged 1 through 23 months.
|
|
Baseline: 13.0 new cases of bacterial meningitis per 100,000 children aged 1 through 23 months were reported in 1998.
|
|
Target setting method: 34 percent improvement. (Better than the best will be used when data are available.)
|
|
Data
source
: Active Bacterial Core Surveillance (ABCs), Emerging Infections Program Network, CDC, NCID.
|
|
|
|
|
|
NO CHANGE IN OBJECTIVE
(Data updated and footnoted)
|
|
14-5.
|
Reduce invasive pneumococcal infections.
|
|
Target and baseline:
|
Objective
|
Reduction in Invasive Pneumococcal Infections
|
1997
Baseline
|
2010
Target
|
|
|
|
Rate per 100,000
|
|
|
New invasive pneumococcal infections
|
|
14-5a.
|
Children under age 5 years
|
771
|
462
|
|
14-5b.
|
Adults aged 65 years and older
|
62
|
42
|
|
|
Invasive penicillin-resistant pneumococcal infections
|
|
14-5c.
|
Children under age 5 years
|
16
|
6
|
|
14-5d.
|
Adults aged 65 years and older
|
83
|
74
|
|
|
Target setting method: Better than the best.
|
|
Data
source
s: Active Bacterial Core Surveillance (ABCs), Emerging Infections Program Network, CDC, NCID; Arctic Investigations Program (for data on pneumococcal disease rates among Alaska Natives), CDC.
|
1 (Baseline revised from 76 after November 2000 publication)
2 (Target revised from 46 because of baseline revision after November 2000 publication)
3 (Baseline revised from 9 after November 2000 publication)
4 (Target revised from 7 because of baseline revision after November 2000 publication)
|
|
|
|
Diseases Preventable Through Targeted Vaccination
NO CHANGE IN OBJECTIVE
(Data updated and footnoted)
|
|
14-6.
|
Reduce hepatitis A.
|
|
|
Target: 4.31 new cases per 100,000 population.
|
|
Baseline: 11.22 new cases of hepatitis A per 100,000 population were reported in 1997.
|
|
Target setting method: Better than the best.
|
|
Data
source
: National Notifiable Disease Surveillance System (NNDSS), CDC, EPO.
|
1 (Target revised from 4.5 because of baseline revision after November 2000 publication)
2 (Baseline revised from 11.3 after November 2000 publication)
|
|
|
|
NO CHANGE IN OBJECTIVE
|
|
14-7.
|
Reduce meningococcal disease.
|
|
|
Target: 1.0 new cases per 100,000 population.
|
|
Baseline: 1.3 new cases of meningococcal disease per 100,000 population were reported in 1997.
|
|
Target setting method: Better than the best.
|
|
Data
source
s: Active Bacterial Core Surveillance (ABCs), Emerging Infections Program Network, CDC, NCID; National Notifiable Diseases Surveillance System (NNDSS), CDC, EPO.
|
|
|
|
|
|
NO CHANGE IN OBJECTIVE
|
|
14-8.
|
Reduce Lyme disease.
|
|
|
Target: 9.7 new cases per 100,000 population in endemic States.
|
|
Baseline: 17.4 new cases of Lyme disease per 100,000 population were reported in 1992–96.
|
|
Target setting method: 44 percent improvement. (Better than the best will be used when data are available.)
|
|
Potential data source: National Notifiable Disease Surveillance System (NNDSS), CDC, EPO.
|
|
|
|
|
|
Infectious Diseases and Emerging Antimicrobial Resistance
NO CHANGE IN OBJECTIVE
(Data updated and footnoted)
|
|
14-9.
|
Reduce hepatitis C.
|
|
|
Target: 1.0 new cases per 100,000 population.
|
|
Baseline: 2.51 new cases of hepatitis C per 100,000 population in selected
counties were reported in 1997.1
|
|
Target setting method: Better than the best.
|
|
Data
source
: Sentinel Counties Study of Viral Hepatitis, CDC, NCID.
|
|
1 (Baseline and baseline year revised from 2.4 and 1996 after November 2000 publication)
|
|
|
|
ORIGINAL OBJECTIVE
|
|
14-10.
|
(Developmental) Increase the proportion of persons with chronic hepatitis C infection identified by State and local health departments.
|
|
|
Potential data sources: State health department databases of persons with HCV infection; National Health and Nutrition Examination Survey (NHANES), CDC, NCHS.
|
|
|
|
|
|
OBJECTIVE WITH REVISIONS
|
|
14-10.
|
(Developmental) Increase the proportion of persons withnumber of States and the District of Columbia identifying persons with chronic hepatitis C infection identified by State and local health departments.
|
|
Potential data sources: National Notifiable Disease Surveillance System (NNDSS), State health department databases of persons with HCV infection; National Health and Nutrition Examination Survey (NHANES),
CDC, EOPNCHS.
|
|
|
|
|
|
REVISED OBJECTIVE
|
|
14-10.
|
(Developmental) Increase the number of States and the District of Columbia identifying persons with chronic hepatitis C infection.
|
|
|
Potential data source: National Notifiable Disease Surveillance System (NNDSS), CDC, EPO.
|
|
|
|
|
|
NO CHANGE IN OBJECTIVE
|
|
14-11.
|
Reduce tuberculosis.
|
|
|
Target: 1.0 new cases per 100,000 population.
|
|
Baseline: 6.8 new cases of tuberculosis per 100,000 population were reported in 1998.
|
|
Target setting method: Better than the best.
|
|
Data
source
: National TB Surveillance System, CDC, NCHSTP.
|
|
|
|
|
|
NO CHANGE IN OBJECTIVE
|
|
14-12.
|
Increase the proportion of all tuberculosis patients who complete curative therapy within 12 months.
|
|
|
Target: 90 percent of patients.
|
|
Baseline: 74 percent of those tuberculosis patients reported in 1996 and started on therapy completed therapy within 12 months.
|
|
Target setting method: Better than the best.
|
|
Data
source
: National TB Surveillance System, CDC, NCHSTP.
|
|
|
|
|
|
ORIGINAL OBJECTIVE
|
|
14-13.
|
Increase the proportion of contacts and other high-risk persons with latent tuberculosis infection who complete a course of treatment.
|
|
|
Target: 85 percent.
|
|
Baseline: 62 percent of tuberculosis contacts and other high-risk persons who started on treatment for latent TB infection in 1997 completed treatment.
|
|
Target setting method: 27 percent improvement. (Better than the best will be used when data are available.)
|
|
Data
source
: Aggregate Reports for TB Reports Evaluation, CDC, NCHSTP.
|
|
|
|
|
|
OBJECTIVE WITH REVISIONS
|
|
14-13.
|
Increase the proportion of contacts and other high-risk persons with latent tuberculosis infection who complete a course of treatment.
|
|
Target: 8557 percent.
|
Baseline: 4562 percent of tuberculosis contacts and other high-risk persons who started on treatment with latent TB infection in 1997 2000 completed treatment.
|
|
Target setting method: 27 percent improvement. (Better than the best will be used when data are available.)
|
|
Data
source
: Aggregate Reports for TB Reports Evaluation, CDC, NCHSTP.
|
|
|
|
|
|
REVISED OBJECTIVE
|
|
14-13.
|
Increase the proportion of persons with latent tuberculosis infection who complete a course of treatment.
|
|
|
Target: 57 percent.
|
|
Baseline: 45 percent of persons with latent TB infection in 2000 completed treatment.
|
|
Target setting method: 27 percent improvement. (Better than the best will be used when data are available.)
|
|
Data
source
: Aggregate Reports for TB Reports Evaluation, CDC, NCHSTP.
|
|
|
|
|
|
NO CHANGE IN OBJECTIVE
|
|
14-14.
|
Reduce the average time for a laboratory to confirm and report tuberculosis cases.
|
|
|
Target: 2 days for 75 percent of cases.
|
|
Baseline: 21 days were needed for a laboratory to confirm and report 75 percent of TB cases in 1996.
|
|
Target setting method: 90 percent improvement.
|
|
Data
source
: Survey of State Public Health Laboratories, CDC, NCHSTP.
|
|
|
|
|
|
OBJECTIVE PROPOSED FOR DELETION
|
|
14-15.
|
(Objective proposed for deletion due to lack of data source) (Developmental) Increase the proportion of international travelers who receive recommended preventive services when traveling in areas of risk for select infectious diseases: hepatitis A, malaria, and typhoid.
Read information regarding the deletion of an objective due to lack of data source.
|
|
|
|
|
|
|
NO CHANGE IN OBJECTIVE
|
|
14-16.
|
Reduce invasive early onset group B streptococcal disease.
|
|
|
Target: 0.5 new cases per 1,000 live births.
|
|
Baseline: 1.0 new case of invasive early onset group B streptococcal disease per 1,000 live births was reported in 1996.
|
|
Target setting method: Better than the best.
|
|
Data
source
: Active Bacterial Core Surveillance (ABCs), Emerging Infections Program Network, CDC, NCID.
|
|
|
|
|
|
NO CHANGE IN OBJECTIVE
|
|
14-17.
|
Reduce hospitalizations caused by peptic ulcer disease in the United States.
|
|
|
Target: 46 hospitalizations per 100,000 population.
|
|
Baseline: 71 hospitalizations per 100,000 population occurred in 1998 (age adjusted to the year 2000 standard population).
|
|
Target setting method: Better than the best.
|
|
Data
source
s: National Hospital Discharge Survey (NHDS), CDC, NCHS.
|
|
|
|
|
|
NO CHANGE IN OBJECTIVE
(Data updated and footnoted)
|
|
14-18.
|
Reduce the number of courses of antibiotics for ear infections for young children.
|
|
|
Target: 561 antibiotic courses per 100 children under age 5 years.
|
|
Baseline: 692 antibiotic courses for otitis media per 100 children under age 5 years were prescribed during 1996–97 (2-year average).
|
|
Target setting method: 19 percent improvement.
|
|
Data
source
s: National Ambulatory Medical Care Survey (NAMCS), CDC, NCHS; National Hospital Ambulatory Medical Care Survey (NHAMCS), CDC, NCHS.
|
1 (Target revised from 88 because of baseline revision after November 2000 publication)
2 (Baseline revised from 108 after November 2000 publication)
|
|
|
|
NO CHANGE IN OBJECTIVE
|
|
14-19.
|
Reduce the number of courses of antibiotics prescribed for the sole diagnosis of the common cold.
|
|
|
Target: 1,268 antibiotic courses per 100,000 population.
|
|
Baseline: 2,535 antibiotic courses per 100,000 population were prescribed for the sole diagnosis of the common cold, 1996–97.
|
|
Target setting method: 50 percent improvement.
|
|
Data
source
s: National Ambulatory Medical Care Survey (NAMCS), CDC, NCHS; National Hospital Ambulatory Medical Care Survey (NHAMCS), CDC, NCHS.
|
|
|
|
|
|
ORIGINAL OBJECTIVE
|
|
14-20.
|
Reduce hospital-acquired infections in intensive care unit patients.
|
|
Target and baseline:
|
Objective
|
Reduction in Hospital-Acquired Infections in Intensive Care Units
|
1998
Baseline
|
2010
Target
|
|
|
|
Infections per 1,000 Days' Use
|
|
|
Intensive care unit patients
|
|
14-20a.
|
Catheter-associated urinary tract infection
|
5.51
|
5.02
|
|
14-20b.
|
Central line-associated bloodstream infection
|
5.53
|
5.04
|
|
14-20c.
|
Ventilator-associated pneumonia
|
11.1
|
10.0
|
|
|
Infants weighing 1,000 grams or less at birth in intensive care
|
|
14-20d.
|
Central line-associated bloodstream infection
|
12.2
|
11.0
|
|
14-20e.
|
Ventilator-associated pneumonia
|
4.9
|
4.4
|
|
|
Target setting method: 10 percent improvement. (Better than the best will be used when data are available.)
|
|
Data
source
: National Nosocomial Infections Surveillance System (NNIS), CDC, NCID.
|
1 (Baseline revised from 5.9 after November 2000 publication)
2 (Target revised from 5.3 because of baseline revision after November 2000 publication)
3 (Baseline revised from 5.3 after November 2000 publication)
4 (Target revised from 4.8 because of baseline revision after November 2000 publication)
|
|
|
|
OBJECTIVE WITH REVISIONS
|
|
14-20.
|
Reduce hospital-acquired infections in intensive care unit patients.
|
|
Target and baseline:
|
Objective
|
Reduction in Hospital-Acquired Infections in Intensive Care Units
|
1998
Baseline
(unless noted)
|
2010
Target
|
|
|
|
Infections per 1,000 Days' Use
|
|
|
Intensive care unit patients
|
|
14-20a.
|
Catheter-associated urinary tract infection
|
5.51
|
5.02
|
|
14-20b.
|
Central line-associated bloodstream infection
|
5.53
|
5.04
|
|
14-20c.
|
Ventilator-associated pneumonia
|
11.1 5.9 (200203)
|
10.0 5.3
|
|
|
Infants weighing 1,000 grams or less at birth in intensive care
|
|
14-20d.
|
Central line-associated bloodstream infection
|
12.2
|
11.0
|
|
14-20e.
|
Ventilator-associated pneumonia
|
4.9 3.0 (200203)
|
4.4 2.7
|
|
|
Target setting method: 10 percent improvement. (Better than the best will be used when data are available.)
|
|
Data
source
: National Nosocomial Infections Surveillance System (NNIS), CDC, NCID.
|
1 (Baseline revised from 5.9 after November 2000 publication)
2 (Target revised from 5.3 because of baseline revision after November 2000 publication)
3 (Baseline revised from 5.3 after November 2000 publication)
4 (Target revised from 4.8 because of baseline revision after November 2000 publication)
|
|
|
|
REVISED OBJECTIVE
|
|
14-20.
|
Reduce hospital-acquired infections in intensive care unit patients.
|
|
Target and baseline:
|
Objective
|
Reduction in Hospital-Acquired Infections in Intensive Care Units
|
1998
Baseline
(unless noted)
|
2010
Target
|
|
|
|
Infections per 1,000 Days' Use
|
|
|
Intensive care unit patients
|
|
14-20a.
|
Catheter-associated urinary tract infection
|
5.51
|
5.02
|
|
14-20b.
|
Central line-associated bloodstream infection
|
5.53
|
5.04
|
|
14-20c.
|
Ventilator-associated pneumonia
|
5.9 (2002-03)
|
5.3
|
|
|
Infants weighing 1,000 grams or less at birth in intensive care
|
|
14-20d.
|
Central line-associated bloodstream infection
|
12.2
|
11.0
|
|
14-20e.
|
Ventilator-associated pneumonia
|
3.0 (2002-03)
|
2.7
|
|
|
Target setting method: 10 percent improvement. (Better than the best will be used when data are available.)
|
|
Data
source
: National Nosocomial Infections Surveillance System (NNIS), CDC, NCID.
|
1 (Baseline revised from 5.9 after November 2000 publication)
2 (Target revised from 5.3 because of baseline revision after November 2000 publication)
3 (Baseline revised from 5.3 after November 2000 publication)
4 (Target revised from 4.8 because of baseline revision after November 2000 publication)
|
|
|
|
ORIGINAL OBJECTIVE
|
|
14-21.
|
Reduce antimicrobial use among intensive care unit patients.
|
|
|
Target: 120 daily doses per 1,000 patient days.
|
|
Baseline: 150 daily doses of antimicrobials per 1,000 patient days were used among intensive care unit patients in 1995.
|
|
Target setting method: 20 percent improvement.
|
|
Data
source
: National Nosocomial Infections Surveillance System (NNIS), CDC, NCID.
|
|
|
|
|
|
OBJECTIVE WITH REVISIONS
|
|
14-21.
|
Reduce antimicrobial vancomycin use among intensive care unit patients.
|
|
Target: 120 85.1 doses per 1,000 patient days.
|
Baseline: 150106.4 doses of vancomycin per 1,000 patient days were used among intensive care unit patients in 19951998–2003.
|
|
Target setting method: 20 percent improvement.
|
|
Data
source
: National Nosocomial Infections Surveillance System (NNIS), CDC, NCID.
|
|
|
|
|
|
REVISED OBJECTIVE
|
|
14-21.
|
Reduce vancomycin use among intensive care unit patients.
|
|
|
Target: 85.1 doses per 1,000 patient days.
|
|
Baseline: 106.4 doses of vancomycin per 1,000 patient days were used among intensive care unit patients in 1998–2003.
|
|
Target setting method: 20 percent improvement.
|
|
Data
source
: National Nosocomial Infections Surveillance System (NNIS), CDC, NCID.
|
|
|
|
|
|
Vaccination Coverage and Strategies
ORIGINAL OBJECTIVE
|
|
14-22.
|
Achieve and maintain effective vaccination coverage levels for universally recommended vaccines among young
children.
|
|
Target and baseline:
|
Objective
|
Increase in and Maintenance of Vaccination Coverage Levels Among Children Aged 19 to 35 Months
|
1998
Baseline
|
2010
Target
|
|
|
|
Percent
|
|
14-22a.
|
4 doses diphtheria-tetanus-acellular pertussis (DTaP) vaccine
|
84
|
90
|
|
14-22b.
|
3 doses Haemophilus influenzae type b (Hib) vaccine
|
93
|
90
|
|
14-22c.
|
3 doses hepatitis B (hep B) vaccine
|
87
|
90
|
|
14-22d.
|
1 dose measles-mumps-rubella (MMR) vaccine
|
92
|
90
|
|
14-22e.
|
3 doses polio vaccine
|
91
|
90
|
|
14-22f.
|
1 dose varicella vaccine
|
43
|
90
|
|
|
Target setting method: Consistent with the Childhood Immunization Initiative.
|
|
Data
source
: National Immunization Survey (NIS), CDC, NCHS and NIP.
|
|
|
|
|
|
OBJECTIVE WITH REVISIONS
|
|
14-22.
|
Achieve and maintain effective vaccination coverage levels for universally recommended vaccines among young
children.
|
|
Target and baseline:
|
Objective
|
Increase in and Maintenance of Vaccination Coverage Levels Among Children Aged 19 to 35 Months
|
1998
Baseline
(unless noted)
|
2010
Target
|
|
|
|
Percent
|
|
14-22a.
|
4 doses diphtheria-tetanus-acellular pertussis (DTaP) vaccine
|
84
|
90
|
|
14-22b.
|
3 doses Haemophilus influenzae type b (Hib) vaccine
|
93
|
90
|
|
14-22c.
|
3 doses hepatitis B (hep B) vaccine
|
87
|
90
|
|
14-22d.
|
1 dose measles-mumps-rubella (MMR) vaccine
|
92
|
90
|
|
14-22e.
|
3 doses polio vaccine
|
91
|
90
|
|
14-22f.
|
1 dose varicella vaccine
|
43
|
90
|
|
14-22g.
|
4 doses pneumococcal conjugate vaccine
|
20 (2002)
|
90
|
|
14-22h.
|
1 dose influenza vaccine (aged 6 to 23 months)
|
Developmental
|
|
|
Target setting method: Consistent with the Childhood Immunization Initiative.
|
|
Data
source
: National Immunization Survey (NIS), CDC, NCHS and NIP.
|
|
|
|
|
|
REVISED OBJECTIVE
|
|
14-22.
|
Achieve and maintain effective vaccination coverage levels for universally recommended vaccines among young
children.
|
|
Target and baseline:
|
Objective
|
Increase in and Maintenance of Vaccination Coverage Levels Among Children Aged 19 to 35 Months
|
1998
Baseline
(unless noted)
|
2010
Target
|
|
|
|
Percent
|
|
14-22a.
|
4 doses diphtheria-tetanus-acellular pertussis (DTaP) vaccine
|
84
|
90
|
|
14-22b.
|
3 doses Haemophilus influenzae type b (Hib) vaccine
|
93
|
90
|
|
14-22c.
|
3 doses hepatitis B (hep B) vaccine
|
87
|
90
|
|
14-22d.
|
1 dose measles-mumps-rubella (MMR) vaccine
|
92
|
90
|
|
14-22e.
|
3 doses polio vaccine
|
91
|
90
|
|
14-22f.
|
1 dose varicella vaccine
|
43
|
90
|
|
14-22g.
|
4 doses pneumococcal conjugate vaccine
|
20 (2002)
|
90
|
|
14-22h.
|
1 dose influenza vaccine (aged 6 to 23 months)
|
Developmental
|
|
|
Target setting method: Consistent with the Childhood Immunization Initiative.
|
|
Data
source
: National Immunization Survey (NIS), CDC, NCHS and NIP.
|
|
|
|
|
|
ORIGINAL OBJECTIVE
|
|
14-23.
|
Maintain vaccination coverage levels for children in licensed day care facilities and children in kindergarten through the first grade.
|
|
Target and baseline:
|
Objective
|
Maintenance of Vaccination Coverage Levels for Children
|
199798
Baseline*
|
2010
Target
|
|
|
|
Percent
|
|
|
Children in day care
|
|
14-23a.
|
Diphtheria-tetanus-acellular pertussis (DTaP) vaccine
|
96
|
95
|
|
14-23b.
|
Measles/mumps/rubella vaccines
|
89
|
95
|
|
14-23c.
|
Polio vaccine
|
96
|
95
|
|
14-23d.
|
Hepatitis B vaccine
|
Developmental
|
|
14-23e.
|
Varicella vaccine
|
Developmental
|
|
|
Children in K through 1st grade
|
|
14-23f.
|
Diphtheria-tetanus-acellular pertussis (DTaP) vaccine
|
97
|
95
|
|
14-23g.
|
Measles/mumps/rubella vaccines
|
96
|
95
|
|
14-23h.
|
Polio vaccine
|
97
|
95
|
|
14-23i.
|
Hepatitis B vaccine
|
Developmental
|
|
14-23j.
|
Varicella vaccine
|
Developmental
|
* Weighted means.
|
|
Target setting method: Consistent with year 2000 target. (Better than the best will be used when data are available.)
|
|
Data
source
: Immunization Program Annual Reports, CDC, NIP.
|
|
|
|
|
|
OBJECTIVE WITH REVISIONS
|
|
14-23.
|
Maintain vaccination coverage levels for children in licensed day care facilities and children in kindergarten through first grade.
|
|
Target and baseline:
|
Objective†
|
Maintenance of Vaccination Coverage Levels for Children
|
199798
Baseline*
(unless noted)
|
2010
Target
|
|
|
|
Percent
|
|
|
Children in day care
|
|
14-23a.
|
Diphtheria-tetanus-acellular pertussis (DTaP) vaccine
|
96
|
95
|
|
14-23b.
|
Measles/mumps/rubella vaccines
|
89
|
95
|
|
14-23c.
|
Polio vaccine
|
96
|
95
|
|
14-23d.
|
Hepatitis B vaccine
|
93 (200304)
Developmental
|
95
|
|
14-23e.
|
Varicella vaccine
|
87 (200304)
Developmental
|
95
|
|
|
Children in K through 1st grade kindergarten
|
|
14-23f.
|
Diphtheria-tetanus-acellular pertussis (DTaP) vaccine
|
9795 (200203)
|
95
|
|
14-23g.
|
Measles/mumps/rubella vaccines
|
96 (200203)
|
95
|
|
14-23h.
|
Polio vaccine
|
976 (200203)
|
95
|
|
14-23i.
|
Hepatitis B vaccine
|
96 (200203)
Developmental
|
95
|
|
14-23j.
|
Varicella vaccine
|
93 (200203)
Developmental
|
95
|
|
|
Children in day care
|
|
14-23k.†
|
Pneumococcal conjugate vaccine
|
53 (200304)
|
95
|
* Weighted means.
† (For data control purposes, subobjectives are not renumbered.)
|
|
Target setting method: Consistent with year 2000 target. (Better than the best will be used when data are available.)
|
|
Data
source
: Immunization Program Annual Reports, CDC, NIP.
|
|
|
|
|
|
REVISED OBJECTIVE
|
|
14-23.
|
Maintain vaccination coverage levels for children in licensed day care facilities and children in kindergarten.
|
|
Target and baseline:
|
Objective†
|
Maintenance of Vaccination Coverage Levels for Children
|
199798
Baseline*
(unless noted)
|
2010
Target
|
|
|
|
Percent
|
|
|
Children in day care
|
|
14-23a.
|
Diphtheria-tetanus-acellular pertussis (DTaP) vaccine
|
96
|
95
|
|
14-23b.
|
Measles/mumps/rubella vaccine
|
89
|
95
|
|
14-23c.
|
Polio vaccine
|
96
|
95
|
|
14-23d.
|
Hepatitis B vaccine
|
93 (2003-04)
|
95
|
|
14-23e.
|
Varicella vaccine
|
87 (2003-04)
|
95
|
|
|
Children in kindergarten
|
|
14-23f.
|
Diphtheria-tetanus-acellular pertussis (DTaP) vaccine
|
95 (2002-03)
|
95
|
|
14-23g.
|
Measles/mumps/rubella vaccine
|
96 (2002-03)
|
95
|
|
14-23h.
|
Polio vaccine
|
96 (2002-03)
|
95
|
|
14-23i.
|
Hepatitis B vaccine
|
96 (2002-03)
|
95
|
|
14-23j.
|
Varicella vaccine
|
93 (2002-03)
|
95
|
|
|
Children in day care
|
|
14-23k.†
|
Pneumococcal conjugate vaccine
|
53 (2003-04)
|
95
|
* Weighted means.
† (For data control purposes, subobjectives are not renumbered.)
|
|
Target setting method: Consistent with year 2000 target. (Better than the best will be used when data are available.)
|
|
Data
source
: Immunization Program Annual Reports, CDC, NIP.
|
|
|
|
|
|
NO CHANGE IN OBJECTIVE
|
|
14-24.
|
Increase the proportion of young children and adolescents who receive all vaccines that have been recommended for universal administration for at least 5 years.
|
|
|
Target and baseline:
|
|
Target setting method: Better than the best.
|
|
Data
source
: National Immunization Survey (NIS), CDC, NCHS and NIP; National Health Interview Survey (NHIS), CDC, NCHS.
|
|
|
|
|
|
ORIGINAL OBJECTIVE
|
|
14-25.
|
Increase the proportion of providers who have measured the vaccination coverage levels among children in their practice population within the past 2 years.
|
|
Target and baseline:
|
Objective
|
Increase in Providers Measuring Vaccination Levels
|
1997
Baseline
|
2010
Target
|
|
|
|
Percent
|
|
14-25a.
|
Public health providers
|
66
|
90
|
|
14-25b.
|
Private providers
|
6
|
90
|
|
|
Target setting method: 36 percent improvement for public health providers; 1,400 percent improvement for private providers.
|
|
Data
source
: Immunization Program Annual Reports, CDC, NIP.
|
|
|
|
|
|
OBJECTIVE WITH REVISIONS
|
|
14-25.
|
Increase the proportion of providers who have had vaccination coverage levels among children in their practice population have measured the vaccination coverage levels among children in their practice population within the past 2 years.
|
|
Target and baseline:
|
Objective
|
Increase in Providers Measuring Vaccination Levels
|
19979
Baseline
|
2010
Target
|
|
|
|
Percent
|
|
14-25a.
|
Public health providers
|
6640
|
9055
|
|
14-25b.
|
Private providers
|
611
|
9055
|
|
Target setting method: 36 percent improvement for public health providers;1,400 391 percent improvement for private providers.
|
|
Data
source
: Immunization Program Annual Reports, CDC, NIP.
|
|
|
|
|
|
REVISED OBJECTIVE
|
|
14-25.
|
Increase the proportion of providers who have had vaccination coverage levels among children in their practice population measured within the past 2 years.
|
|
Target and baseline:
|
Objective
|
Increase in Providers Measuring Vaccination Levels
|
1999
Baseline
|
2010
Target
|
|
|
|
Percent
|
|
14-25a.
|
Public health providers
|
40
|
55
|
|
14-25b.
|
Private providers
|
11
|
55
|
|
|
Target setting method: 36 percent improvement for public health providers; 391 percent improvement for private providers.
|
|
Data
source
: Immunization Program Annual Reports, CDC, NIP.
|
|
|
|
|
|
NO CHANGE IN OBJECTIVE
(Data updated and footnoted)
|
|
14-26.
|
Increase the proportion of children who participate in fully operational population-based immunization registries.
|
|
|
Target: 621 percent of children under age 6 years.
|
|
Baseline: 212 percent of children under age 6 years participated in an immunization registry in 1999.
|
|
Target setting method: 197 percent improvement. (Better than the best will be used when data are available.)
|
|
Data
source
: Immunization Program Annual Reports, CDC, NIP.
|
1 (Target revised from 95 because of baseline revision after November 2000 publication)
2 (Baseline revised from 32 after November 2000 publication)
|
|
|
|
NO CHANGE IN OBJECTIVE
|
|
14-27.
|
Increase routine vaccination coverage levels for adolescents.
|
|
Target and baseline:
|
Objective
|
Increase in Vaccination Coverage Levels for Adolescents Aged 13 to 15 Years
|
1997
Baseline*
|
2010
Target
|
|
|
|
Percent
|
|
14-27a.
|
3 or more doses of hepatitis B
|
48
|
90
|
|
14-27b.
|
2 or more doses of measles, mumps, rubella
|
89
|
90
|
|
14-27c.
|
1 or more doses of tetanus-diphtheria booster
|
93
|
90
|
|
14-27d.
|
1 or more doses of varicella (excluding children who have had varicella)
|
45
|
90
|
* Data primarily are based on parental recall; provider verification has not occurred.
|
|
Target setting method: Consistent with target levels established under Childhood Immunization Initiative.
|
|
Data
source
: National Health Interview Survey (NHIS), CDC, NCHS.
|
|
|
|
|
|
NO CHANGE IN OBJECTIVE
(Data updated and footnoted)
|
|
14-28.
|
Increase hepatitis B vaccine coverage among high-risk groups.
|
|
Target and baseline:
|
Objective
|
Increase in Hepatitis B Vaccine Coverage in High-Risk Groups
|
1995
Baseline
|
2010
Target
|
|
|
|
Percent
|
|
14-28a.
|
Long-term hemodialysis patients
|
35
|
90
|
|
14-28b.
|
Men who have sex with men
|
9
|
60
|
|
14-28c.
|
Occupationally exposed workers
|
671
|
932
|
|
|
Target setting method: 157 percent improvement for long-term hemodialysis patients; 567 percent improvement for men who have sex with men; 38 percent improvement for occupationally exposed workers.
|
|
Data
source
s: Young Men’s Survey, CDC, NCHSTP; Annual Survey of Chronic Hemodialysis Centers, CDC, NCID, and HCFA; periodic vaccine coverage surveys, CDC, NCID.
|
1 (Baseline revised from 71 after November 2000 publication)
2 (Target revised from 98 because of baseline revision after November 2000 publication)
|
|
|
|
ORIGINAL OBJECTIVE
|
|
14-29.
|
Increase the proportion of adults who are vaccinated annually against influenza and ever vaccinated against pneumococcal disease.
|
|
Target and baseline:
|
Objective
|
Increase in Adults Vaccinated
|
1998
Baseline*
(unless noted)
|
2010
Target
|
|
|
|
Percent
|
|
|
Noninstitutionalized adults aged 65 years and older
|
|
|
|
14-29a.
|
Influenza vaccine
|
64
|
90
|
|
14-29b.
|
Pneumococcal vaccine
|
46
|
90
|
|
|
Noninstitutionalized high-risk adults aged 18 to 64 years
|
|
|
|
14-29c.
|
Influenza vaccine
|
26
|
60
|
|
14-29d.
|
Pneumococcal vaccine
|
13
|
60
|
|
|
Institutionalized adults (persons in long-term or nursing homes)†
|
|
|
|
14-29e.
|
Influenza vaccine
|
59 (1997)
|
90
|
|
14-29f.
|
Pneumococcal vaccine
|
25 (1997)
|
90
|
* Age adjusted to the year 2000 standard population.
† National Nursing Home Survey estimates include a significant number of residents who have an unknown vaccination status. See Tracking Healthy People 2010 for further discussion of the data issues.
|
|
Target setting method: Better than the best.
|
|
Data
source
s: National Health Interview Survey (NHIS), CDC, NCHS—noninstitutionalized populations; National Nursing Home Survey (NNHS), CDC, NCHS—institutionalized populations.
|
|
|
|
|
|
OBJECTIVE WITH REVISIONS
|
|
14-29.
|
Increase the proportion of adults who are vaccinated annually against influenza and ever vaccinated against pneumococcal disease.
|
|
Target and baseline:
|
Objective
|
Increase in Adults Vaccinated
|
1998
Baseline*
(unless noted)
|
2010
Target
|
|
|
|
Percent
|
|
|
Noninstitutionalized adults aged 65 years and older
|
|
|
|
14-29a.
|
Influenza vaccine
|
64
|
90
|
|
14-29b.
|
Pneumococcal vaccine
|
46
|
90
|
|
|
Noninstitutionalized high-risk adults aged 18 to 64 years
|
|
|
|
14-29c.
|
Influenza vaccine
|
26
|
60
|
|
14-29d.
|
Pneumococcal vaccine
|
13
|
60
|
|
|
Institutionalized adults (persons aged 18 years and older in long-term or nursing homes)†
|
|
|
|
14-29e.
|
Influenza vaccine
|
59 (1997)
|
90
|
|
14-29f.
|
Pneumococcal vaccine
|
25 (1997)
|
90
|
|
|
Noninstitutionalized high-risk adults aged 18 to 64 years
|
|
|
|
14-29g.
|
Influenza vaccine for health care workers
|
37 (2000)
|
60
|
* Age adjusted to the year 2000 standard population.
† National Nursing Home Survey estimates include a significant number of residents who have an unknown vaccination status. See Tracking Healthy People 2010 for further discussion of the data issues.
|
|
Target setting method: Better than the best.
|
|
Data
source
s: National Health Interview Survey (NHIS), CDC, NCHS—noninstitutionalized populations; National Nursing Home Survey (NNHS), CDC, NCHS—institutionalized populations.
|
|
|
|
|
|
REVISED OBJECTIVE
|
|
14-29.
|
Increase the proportion of adults who are vaccinated annually against influenza and ever vaccinated against pneumococcal disease.
|
|
Target and baseline:
|
Objective
|
Increase in Adults Vaccinated
|
1998
Baseline*
(unless noted)
|
2010
Target
|
|
|
|
Percent
|
|
|
Noninstitutionalized adults aged 65 years and older
|
|
|
|
14-29a.
|
Influenza vaccine
|
64
|
90
|
|
14-29b.
|
Pneumococcal vaccine
|
46
|
90
|
|
|
Noninstitutionalized high-risk adults aged 18 to 64 years
|
|
|
|
14-29c.
|
Influenza vaccine
|
26
|
60
|
|
14-29d.
|
Pneumococcal vaccine
|
13
|
60
|
|
|
Institutionalized adults (persons aged 18 years and older in long-term or nursing homes)†
|
|
|
|
14-29e.
|
Influenza vaccine
|
59 (1997)
|
90
|
|
14-29f.
|
Pneumococcal vaccine
|
25 (1997)
|
90
|
|
|
Noninstitutionalized high-risk adults aged 18 to 64 years
|
|
|
|
14-29g.
|
Influenza vaccine for health care workers
|
37 (2000)
|
60
|
* Age adjusted to the year 2000 standard population.
† National Nursing Home Survey estimates include a significant number of residents who have an unknown vaccination status. See Tracking Healthy People 2010 for further discussion of the data issues.
|
|
Target setting method: Better than the best.
|
|
Data
source
s: National Health Interview Survey (NHIS), CDC, NCHS—noninstitutionalized populations; National Nursing Home Survey (NNHS), CDC, NCHS—institutionalized populations.
|
|
|
|
|
|
Vaccine Safety
NO CHANGE IN OBJECTIVE
|
|
14-30.
|
Reduce vaccine-associated adverse events.
|
|
14-30a. Eliminate vaccine-associated paralytic polio (VAPP).
Target: Zero cases.
Baseline: 5 VAPP cases occurred in 1997.
Target setting method: Total elimination.
Data source: National Notifiable Disease Surveillance System (NNDSS), CDC, EPO.
14-30b. Reduce febrile seizures following pertussis vaccines.
Target: 75 febrile seizures.
Baseline: 152 febrile seizures followed pertussis vaccines in 1998.
Target setting method: 50 percent improvement.
Data sources: Vaccine Adverse Event Reporting System (VAERS); Vaccine Safety Datalink (VSD), CDC, NIP.
|
|
|
|
|
|
ORIGINAL OBJECTIVE
|
|
14-31.
|
Increase the number of persons under active surveillance for vaccine safety via large linked databases.
|
|
|
Target: 13 million persons.
|
|
Baseline: 6 million persons were under active surveillance for vaccine safety via large linked databases in 1999.
|
|
Target setting method: 117 percent improvement.
|
|
Data
source
: Vaccine Safety Datalink, CDC, NIP.
|
|
|
|
|
|
OBJECTIVE WITH REVISIONS
|
|
14-31.
|
Increase the number of persons under active surveillance for vaccine safety via large linked databases scientific knowledge on vaccines and adverse events.
|
|
Target and baseline:
|
Objective
|
Increase in the Scientific Knowledge on Vaccines and Adverse Events
|
1999
Baseline
(unless noted)
|
2010
Target
|
|
|
|
Number of Persons (in Millions)
|
|
14-31a.
|
Persons under active surveillance for vaccine safety via large linked databases
|
6
|
13
|
|
|
|
Percent
|
|
14-31b.
|
Proportion of total Vaccine Adverse Event Reporting System (VAERS) reports submitted electronically
|
12 (2003)
|
30
|
|
|
Target setting method: For 14-31a, 117 percent improvement; for 14-31b, expert judgment and knowledge of programs currently in place.
|
|
Data
source
s: Vaccine Safety Datalink, CDC, NIP; Vaccine Adverse Events Reporting System (VAERS), CDC, NIP.
|
|
|
|
|
|
REVISED OBJECTIVE
|
|
14-31.
|
Increase the scientific knowledge on vaccines and adverse events.
|
|
Target and baseline:
|
Objective
|
Increase in the Scientific Knowledge on Vaccines and Adverse Events
|
1999
Baseline
(unless noted)
|
2010
Target
|
|
|
|
Number of Persons (in Millions)
|
|
14-31a.
|
Persons under active surveillance for vaccine safety via large linked databases
|
6
|
13
|
|
|
|
Percent
|
|
14-31b.
|
Proportion of total Vaccine Adverse Event Reporting System (VAERS) reports submitted electronically
|
12 (2003)
|
30
|
|
|
Target setting method: For 14-31a, 117 percent improvement; for 14-31b, expert judgment and knowledge of programs currently in place.
|
|
Data
source
s: Vaccine Safety Datalink, CDC, NIP; Vaccine Adverse Event Reporting System (VAERS), CDC, NIP.
|
|
|
|
|
|
|